MEI Pharma announced Thursday that Christine A. White, M.D., has decided to retire and won’t stand for reelection as chair of the board.

Subsequently, Charles V. Baltic III, J.D., was elected as new chair of the board. Baltic has served as director of MEI since 2011 and been chair of the nominating and governance committee since 2012. Baltic most recently served as COO of SIDIS Corp., with a prior stint at Needham & Company LLC.

MEI said these leadership changes are effective as of the company’s 2023 fiscal year annual meeting of shareholders.

“Although we will miss Christine, we are very fortunate to have Charles as our chair elect. We look forward to working with Charles in his new capacity as board chair to leverage his history and familiarity with MEI,” MEI CEO Daniel P. Gold, PhD, said in a statement. “His extensive industry and professional experience will be invaluable in advancing our mission to improve outcomes for patients with cancer through our efforts to develop and commercialize novel, best-in-class therapies.”